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Abstract The protein kinase C (PKC) family of serine/
threonine kinases consists of ten different isoforms grouped
into three subfamilies, denoted classical, novel and atypical
PKCs (aPKCs). The aPKCs, PKCi/k and PKCf serve
important roles during development and in processes sub-
verted in cancer such as cell and tissue polarity, cell
proliferation, differentiation and apoptosis. In an effort to
identify novel interaction partners for aPKCs, we per-
formed a yeast two-hybrid screen with the regulatory
domain of PKCi/k as bait and identiﬁed the Kru ¨ppel-like
factors family protein TIEG1 as a putative interaction
partner for PKCi/k. We conﬁrmed the interaction of both
aPKCs with TIEG1 in vitro and in cells, and found that
both aPKCs phosphorylate the DNA-binding domain
of TIEG1 on two critical residues. Interestingly, the
aPKC-mediated phosphorylation of TIEG1 affected its
DNA-binding activity, subnuclear localization and trans-
activation potential.
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Abbreviations
DBD DNA-binding domain
TIEG1 Transforming growth factor-b-inducible
early response gene 1
aPKC Atypical protein kinase C
GMSA Gel mobility shift assay
GFP Green ﬂuorescent protein
FRAP Fluorescence recovery after photobleaching
Introduction
The protein kinase C family is composed of ten related
serine/threonine protein kinases, which are divided into
three subfamilies including conventional, novel and atyp-
ical PKCs (aPKCs). PKCf and i/k represent the aPKC
isoforms, where PKCi is the human and PKCk the murine
isoform. The aPKCs differ from the other PKCs by having
an N-terminal PB1 domain and their activation is inde-
pendent of calcium, phorbol esters and diacylglycerol
(reviewed in [1]). However, it has been demonstrated that
the phorbol ester PMA activates PI3K and subsequently
PKCf [2]. The PB1 domain of aPKCs interacts with Par6
and is important for their incorporation into the apical
polarity complex which contains the Par3/Par6/aPKC
module (reviewed in [3]). The activity of the aPKCs is
regulated by 3-phosphoinositides, phosphorylation by the
phosphoinositide-dependent kinase PDK1 and through
speciﬁc protein-protein interactions (reviewed in [4]). Due
to their strong homology (78%) it has been difﬁcult to
distinguish the individual functions of the PKCf and i/k
isoforms. However, PKCi/k is ubiquitously expressed,
while PKCf has a more restricted expression pattern [5].
The murine PKCk differs only from the human PKCi at 10
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123out of 596 amino acid positions (98% sequence identity).
PKCk is essential for embryonic development in the
mouse, whereas PKCf-deﬁcient mice develop nearly nor-
mally [6]. Conditional knock-out studies in mice and frog
have shown that PKCk plays a role in glucose transport and
induction of metabolic and diabetic syndromes [6, 7], and
that it controls the establishment of apicobasal polarity,
adherens junctions and neuroepithelial tissue architecture
in early vertebrate development [8, 9]. Both aPKC iso-
forms are critical for cell survival signaling, and many
studies indicate a correlation between the expression or
activation of aPKC and sensitivity to apoptosis (reviewed
in [1, 4]). The aPKCs seem to be dynamically regulated by
agents inducing cell death, and recent results indicate that
they may act as a switch between cell survival and cell
death (reviewed in [1, 4]).
Transforming growth factor-b-inducible early response
gene 1 (TIEG1) was originally discovered as the product of
a TGFb-inducible early response gene in human osteoblasts
[10]. It was later shown that overexpression of TIEG1
mimics TGFb action and induces apoptosis and decreased
proliferation in several cell lines (reviewed in [11, 12]).
TIEG1 is also known as KLF10 and belongs to the Kru ¨ppel-
like factors (KLF) family of proteins, constituting more
than 20 family members in humans, including Sp1 as the
most well-known member [13]. The C-terminal DNA-
binding domain (DBD) of KLF family proteins consists of
three highly conserved tandem Cys2His2 zinc ﬁnger motifs.
Most KLF family proteins have similar afﬁnity for different
GC-rich promoter elements, and the amino acids that are
predicted to interact with DNA are identical among several
members. Importantly, competition for DNA binding has
been reported for some of the factors (reviewed in [13]). In
addition to DNA binding, the zinc ﬁnger motifs may also
function in protein-protein interactions and are the target for
post-translational modiﬁcations such as phosphorylation,
acetylation and O-linked b-N-acetyl glucose amine addition
(hereafter referred to as O-GlcNAc) [14]. The N-terminal
regions of KLF family members are much less conserved,
containing various transcriptional activation and/or repres-
sion domains. Thus, different family members vary broadly
in their ability to regulate transcription. However, most
members can function either as activators or repressors,
depending on the speciﬁc cellular and promoter contexts
[11, 13]. The KLF factor TIEG1 is reported to induce
and repress the expression of multiple genes, including
p21
Cip1/WAF1, and to function as an inhibitor of cell prolif-
eration and an inducer of apoptosis (reviewed in [12]).
TIEG1 is suggested to function as a tumour suppressor as its
expression inversely correlates with the severity and stage
of breast cancer [15].
In the present study we show that TIEG1 is a substrate
of the aPKCs f and i/k. Two amino acid residues in the
DBD were mapped as the major targets for phosphoryla-
tion, S384 located in zinc ﬁnger 1 and T445 in zinc ﬁnger
3. Phosphorylation of S384 signiﬁcantly reduced the
DNA-binding activity, whereas the T445 phosphorylation
enhanced the TIEG1-mediated transcriptional activation of
the p21
Cip1/WAF1 promoter. Importantly, both phosphory-
lations resulted in subnuclear redistribution of TIEG1,
strengthening the observation that phosphorylation of these
residues in the DBD affects protein-protein and/or protein-
DNA interactions. We also show that in addition to TIEG1,
the DBD of other members of the KLF family proteins may
be regulated by phosphorylation mediated by the aPKCs.
Materials and methods
Antibodies and reagents
The following primary antibodies were used: rabbit poly-
clonal antibody to PKCf (C-20) (SC-216), rabbit
polyclonal antibody to GST (Z-5, SC-459) (Santa Cruz
Biotechnology), rabbit polyclonal antibody to green ﬂuo-
rescent protein (GFP) (ab290) (Abcam), rabbit polyclonal
to beta-actin (A2066) (Sigma-Aldrich), mouse monoclonal
antibody to PKCk (610207) and the secondary antibodies
HRP-conjugated goat anti-rabbit IgG (554021), and goat
anti-mouse IgG (554002) antibodies were purchased from
BD Bioscience Pharmingen. PKCi, active (14-505) and
PKCf, active (14-525) are purchased from Upstate.
Yeast two-hybrid screen
The yeast two-hybrid screen was carried out with the
Matchmaker system (Clontech) according to the manufac-
turer’s instructions. The regulatory domain of PKCk
(pGBKT7-PKCkreg) fused to the Gal4 DBD was used
as bait. This bait was transformed into Saccharomyces
cerevisiae strain PJ69-2A (Clontech) and then mated with
the Y187 strain pretransformed with a HeLa cell cDNA
library fused to the Gal4 activation domain (Clontech).
Approximately 10
6 diploids were screened and tested for
their ability to grow on yeast minimal medium lacking
leucine, tryptophane, histidine, and adenine. Positive
colonies were lysed by incubating them for 1–2 h in a
glucuronidase-containing buffer [(50 mM Tris-HCl (pH
7.5), 10 mM EDTA, 0.3% (v/v) b-mercaptoethanol, and
1:50 glucuronidase (G7017, Sigma)] followed by vortexing
with glass beads (G1145, Sigma) for 5 min. The lysates
were diluted with 100 llH 2O, centrifuged brieﬂy in a
microcentrifuge at maximum speed, and 2 ll of each
sample was analyzed by PCR using the REDTaq ReadyMix
(R2523, Sigma). The PCR products were treated with
exonuclease I (USB) and shrimp alkaline phosphatase
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123(M820A, Promega) followed by sequencing using the Big-
Dye sequencing kit (Applied Biosystems). The sequenced
products were identiﬁed by searching the National Center
for Biotechnology Information (NCBI) using the basic local
alignment search tool (BLAST) algorithm. In order to
verify speciﬁc interactions, clones were re-screened as
described previously [16].
Plasmids
Plasmids used in this work are listed in Table 1. Point
mutations were generated using the QuickChange site
directed mutagenesis kit (Stratagene), and Gateway
destination plasmids were made using Gateway LR
recombination reactions (Invitrogen) following the manu-
facturer’s instructions. All plasmid constructs made in
this study were veriﬁed by DNA sequencing (BigDye
sequencing kit, Applied Biosystems). The oligonucleotides
used for mutagenesis, PCR, and DNA sequencing were
purchased from Operon.
Cell culture and transfections
HeLa cells and U2OS cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS), penicillin (100 U/ml) and
streptomycin (100 lg/ml). Subconﬂuent cells were trans-
fected with the different expression constructs using either
Lipofectamine Plus (Invitrogen) or Metafectene Pro
(Biontex) as recommended by the manufacturers.
Immunoprecipitations and immunoblots
Transfected cells were rinsed with ice-cold PBS prior to
lysis in RIPA buffer [50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40 (v/v), 0.25% Triton X-100
(v/v)] supplemented with Complete Mini EDTA-free
protease inhibitor cocktail tablets (1 tablet per 10 ml)
(11836170001, Roche Applied Science). Lysates were
cleared by centrifugation followed by 30-min incubation
with protein A-agarose beads (SC-2001, Santa Cruz Bio-
technology). The precleared lysates were then incubated
with the indicated primary antibodies overnight at 4C and
then with Protein A-agarose beads for an additional 1 h.
Precipitated immunocomplexes were washed ﬁve times
with RIPA buffer, eluted by boiling for 5 min in SDS-
PAGE loading buffer. Samples were subsequently resolved
by SDS-PAGE and transferred to Hybond-ECL nitrocel-
lulose membranes (Amersham). After blocking unspeciﬁc
binding sites by incubating the membranes for 1 h in 5%
(w/v) non-fat dry milk in TBST [10 mM Tris-HCl (pH
7.5), 150 mM NaCl, 0.1% (v/v) Tween 20], blots were
probed with the indicated primary antibodies overnight at
4C and then by horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h at room temperature. The
membranes were washed six times (5 min each) with
TBST prior to detection with Western Blotting Luminal
Reagent kit (SC-2048, Santa Cruz Biotechnology) and a
LumiAnalyst imager (Roche Applied Sciences).
GST pulldown assays
GST protein was expressed in Escherichia coli LE392 and
MBP in E. coli DB 3.1. GST and MBP-tagged proteins
were expressed in E. coli BL21 STAR (DE3)pLysS cells
(Invitrogen). GST and GST-fusion proteins were puriﬁed
and immobilized on glutathione-coupled sepharose beads
(Glutathione-sepharose 4 Fast Flow, Amersham Biosci-
ence). MBP and MBP-tagged proteins were puriﬁed using
amylose resin (New England Biolabs). GST pulldown
assays were performed by incubating GST and GST-fusion
proteins either with in vitro translated proteins or with
mammalian cell lysate.
35S-labeled proteins were produced
using the TNT T7 Quick Coupled Transcription/Transla-
tion System (Promega) in the presence of [
35S] methionine
(Amersham Biosciences). The synthesized proteins were
diluted 209 with NET-N buffer (20 mM Tris-HCl, pH 8.0,
100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40) con-
taining Complete Mini EDTA-free protease inhibitor
cocktail. The diluted products were pre-cleared by incu-
bating with glutathione-coupled sepharose beads for
30 min prior to incubation with puriﬁed GST or GST-
fusion proteins for at least 2 h at 4C with gentle agitation.
Unbound proteins were removed by washing the resins ﬁve
times with NET-N buffer. The proteins were then eluted by
boiling for 5 min in SDS gel loading buffer and separated
by SDS-PAGE. After vacuum drying the gel,
35S-labeled
proteins were detected on a Fujiﬁlm bioimaging analyzer
BAS-5000 (Fuji). Lysates were prepared from conﬂuent
HeLa cells in 100 mm culture dishes as indicated above,
except that glutathione-coupled agarose beads were used
instead of protein A-agarose beads. Pulldown of PKCi/f
from precleared HeLa cell lysates was also done as
described for pulldown of
35S labeled proteins, except that
proteins separated by SDS-PAGE were subjected to
immunoblot analysis.
In vitro phosphorylation assays
In vitro phosphorylation assays of TIEG1 and its mutants
by the aPKCs were carried out in a total volume of 30 ll,
containing kinase buffer [35.5 mM Tris-HCl (pH 7.5),
10 mM MgCl, 0.5 mM EGTA (pH 8.0), 0.1 mM CaCl2,
Complete Mini EDTA-free protease inhibitor cocktail and
phosphatase inhibitor cocktail set II (1:100) (524625,
Calbiochem)] and 50 ng recombinant active kinase. The
aPKC phosphorylation of TIEG1 1955
123Table 1 Plasmids used in this study
Vectors Description Source
pENTR3C Gateway entry vector Invitrogen
pDONR207 Gateway donor vector Invitrogen
pDest15 Bacterial GST fusion expression vector; T7 promoter Invitrogen
pGEX-4T-1 Bacterial GST fusion expression vector; tac promoter Amersham
pDest53 Mammalian GFP fusion expression vector; CMV and T7
promoter
Invitrogen
pDestTH1 Bacterial MBP fusion expression vector; tac promoter [59]
pDestEGFP-C1 Mammalian EGFP fusion expression vector; CMV promoter [60]
pDestMyc Mammalian Myc fusion expression vector; CMV
and T7 promoter
[60]
pDestHA Mammalian HA fusion expression vector; CMV promoter [60]
pGEX-KG-SKS-Sp1(DBD) Bacterial GST fusion expression vector; tac promoter [61]
pGEX-KG-SKS-BTEB1(DBD) Bacterial GST fusion expression vector; tac promoter [61]
pGEX-KG-SKS-Sp3(DBD) Bacterial GST fusion expression vector; tac promoter [61]
pGEX-KG-SKS-BTEB2(DBD) Bacterial GST fusion expression vector; tac promoter [61]
p21-Luc [56]
pDestMyc-PKCk Murine PKCk in entry vector [60]
cDNA constructs made by traditional cloning or site directed mutagenesis
pDONR207-TIEG1 Human TIEG1(1–480) in donor vector This study
pENTR3C-TIEG1(1–362) Human TIEG1(1–362) in entry vector This study
pENTR3C-TIEG1(DBD) Human TIEG1(363–480) in entry vector This study
pENTR3C-Sp1 Human Sp1(1–785) in entry vector This study
pENTR3C-KLF4 Human KLF4 (1–470) in entry vector This study
pENTR3C-KLF4(DBD) Human KLF4 (381–470) in entry vector This study
pENTR3C-Egr1 Human Egr1(1–543) in entry vector This study
pENTR3C-TIEG1(1–362)Sp1(DBD) Human TIEG1(1–362)Sp1(619–714) in entry vector This study
pENTR3C-TIEG1(DBD)S384A Human TIEG1(363–480) with S384A point mutation
in entry vector
This study
pENTR3C-TIEG1(DBD)T445A Human TIEG1(363–480) with T445A point mutation
in entry vector
This study
pENTR-TIEG1(DBD)S384A/T445A Human TIEG1(363–480) with S384A/T445A point
mutations in entry vector
This study
pENTR3C-TIEG1(DBD)S384E Human TIEG1(363–480) with S384E point mutation
in entry vector
This study
pENTR3C-TIEG1(DBD)T445E Human TIEG1(363–480) with T445E point mutation
in entry vector
This study
pENTR3C-TIEG1(DBD)S384E/T445E Human TIEG1(363–480) with S384E/T445E point
mutations in entry vector
This study
pDONR207-TIEG1S384A Human TIEG1 with S384A point mutation in donor vector This study
pDONR207-TIEG1T445A Human TIEG1 with T445A point mutation in donor vector This study
pDONR207-TIEG1S384A/T445A Human TIEG1 with S384A/T445A point mutations in donor
vector
This study
pDONR207-TIEG1S384E Human TIEG1 with S384E point mutation in donor vector This study
pDONR207-TIEG1T445E Human TIEG1 with T445E point mutation in donor vector This study
pDONR207-TIEG1S384E/T445E Human TIEG1 with S384E/T445E point mutations
in donor vector
This study
pGEX-KG-SKS-Sp1(DBD)S641A Human Sp1(DBD) with S641A point mutation
in expression vector
This study
pGEX-KG-SKS-Sp1(DBD)S702A Human Sp1(DBD) with S702A point mutation
in expression vector
This study
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123enzyme reactions were initiated by the addition of 60 lM
unlabeled ATP and 2 lCi [c-
32P] ATP (Amersham). After
incubation at 30C for 20 min, the reactions were termi-
nated by the addition of SDS gel loading buffer and
subsequent boiling for 5 min. The phosphorylated proteins
were then analyzed by SDS-PAGE and autoradiography.
The time courses of in vitro phosphorylations by PKCf
were performed by preparing 90 ll enzyme reactions and
by withdrawing a 7-ll aliquot at the desired time points.
The aliquots were transferred to microcentrifuge tubes
containing SDS gel loading buffer and analyzed as
described above. Where indicated, quantiﬁcations of the
phosphorylated proteins and the corresponding background
bands were done using the Fuji Image Gauge software
(version 4.0; Fujiﬁlm, Tokyo, Japan). The results are pre-
sented as bar graphs after background subtraction.
Gel mobility shift assay (GMSA)
The following two sets of oligonucleotides (shown 50 to 30)
were used for GMSA: set I (for TIEG1) described in [17]
and set II (for KLF4 and Sp1) described in [18].
Set I: 50-TGCAGTGAAAAGGGGGTGTGTCAGGAT
GC-30, and 50-TGCATC CTGACACACCCCCTTTTCAC
TGC-30; set II: 50-CTTAACATTCCTTTCCCCACCCACA
CAGCTAGTTCCAACC-30, and 50-GGTTGGAACTAG
CTGTGTGGGTGGGGAAAGGAATGTTAAG -30. The
DBDs of TIEG1, Sp1 and KLF4 were expressed and
puriﬁed as described above and eluted in 50 mM Tris-HCl
(pH 8.0) containing 10 mM reduced glutathione. The sense
and antisense strands were annealed in annealing buffer
[10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 100 mM
NaCl] and annealed by heating to 100C for 3 min and
cooling gradually to room temperature. The probes were
labeled with [c-
32P] ATP using T4 polynucleotide kinase
(Takara) and then puriﬁed and eluted using QIA quick
nucleotide removal kit (QIAGEN) as per the recommen-
dation of the manufacturer. The binding reaction mixtures,
containing approximately 500 ng to 1 lg protein, 1 lg
poly (dI-dC) and binding buffer [for TIEG1: 4% Ficoll,
10 mM HEPES (pH 7.9), 30 mM KCl, 0.1 mM EDTA,
1m MN a 2HPO4, 4 mM spermidine and 0.5 mM DTT; and
for KLF4 and Sp1: 4% Ficoll, 10 mM HEPES (pH 7.9),
60 mM KCl, 1 mM EDTA, and 1 mM DTT] were incu-
bated at room temperature for 10 min and then mixed with
3–4 9 10
4 cpm of each probe and incubated for an addi-
tional 20 min. The DNA-protein complexes were resolved
on pre-run 5% polyacrylamide gels (39:1) in 0.59 TBE
buffer (44.5 mM Tris, 44.5 mM boric acid and 2 mM
EDTA) at 230 v for 3 h. Where indicated, GST-tagged
proteins were incubated with 100 ng of active PKCf for
45 min prior to GMSA under the aforementioned kinase
reaction conditions except for the omission of [c-
32P] ATP
from the reaction mixture.
Cell imaging
Cells were seeded at a density of 10
4 cells/well in eight-
well coverglass slides (Nunc) and transfected with 100 ng
plasmid expression vectors 24 h later using lipofectamin
Table 1 continued
Vectors Description Source
pGEX-KG-SKS-Sp1(DBD)S641A/S702A Human Sp1(DBD) with S641A/S702A point
mutations in expression vector
This study
pGEX-KG-SKS-Sp1(DBD)S641E/S702E Human Sp1(DBD) with S641E/S702E point
mutations in expression vector
This study
pENTR-PKCk reg Murine PKCk (1–247) in entry vector This study
cDNA constructs made by Gateway LR reaction (this study)
pDestMyc-PKCk pDest15-TIEG1(DBD)S384A pDest53-TIEG1(DBD)
pDestGBKT7-PKCk reg pDest15-TIEG1(DBD)T445A pDestHA-TIEG1
pDestEGFP-TIEG1S384A pDest15-TIEG1(DBD)S384A/T445A pDestHA-KLF4
pDestEGFP-TIEG1T445A pDest15-TIEG1(DBD)S384E pDestHA-Sp1
pDestEGFP-TIEG1S384A/T445A pDest15-TIEG1(DBD)T445E pDest3X-FLAG-Sp1
pDestEGFP-TIEG1S384E pDest15-TIEG1(DBD)S384E/T445E pDestMyc-TIEG1
(1–362)Sp1(DBD)
pDestEGFP-TIEG1T445E pDestTH1- TIEG1 pDestMyc-KLF11
pDestEGFP-TIEG1S384E/T445E pDestTH1- TIEG1S384A pDestHA-KLF11
pDest15-TIEG1 pDestTH1- TIEG1T445A pDestEGFP-EGR1
pDest15-TIEG1(1–362) pDestTH1- TIEG1S384A/T445A
pDest15-TIEG1(DBD) pDest15-KLF4(DBD)
aPKC phosphorylation of TIEG1 1957
123Plus (Invitrogen). One day after transfection cells were
analyzed by live cell confocal microscopy using a Zeiss
Axiovert 200 microscope with a 409, 1.2 W C-Apochroma
objective, equipped with an LSM510-META confocal
module using the LSM 5 software version 3.2 (Carl Zeiss
Inc.).
Fluorescence recovery after photobleaching (FRAP)
FRAP experiments were carried out with cells plated and
transfected as described above and imaged using a Leica
TCS SP5 confocal microscope, 639, 1.2 W objective,
equipped with an incubation chamber with CO2 and tem-
perature control. Cells were imaged with an argon 488-nm
laser at 50% laser power and a pinhole setting of one.
A circular area of 5 lM in diameter of the cell nucleus was
analyzed using the following conditions: 5 prebleach
images per 0.113 s, 10 bleach pulses per 0.113 s, 300
postbleach images per 0.113 s, 50 postbleach images per
second and ﬁnally 45 postbleach images per 5 s. For
imaging, laser power was attenuated to 5% of bleach
intensity. A total of ten cells were analyzed per plasmid
construct for each independent experiment, and the
experiments were performed at least three times. Individual
FRAP curves were background subtracted and corrected
for loss of ﬂuorescence caused by photobleaching during
imaging.
Reporter gene assays
U2OS cells were seeded at a density of 4 9 10
4 cells/well
in 24-well plates and transfected 24 h later using Meta-
fectene Pro. Transfections were performed with 100 or
250 ng of the various protein expression plasmids together
with 100 ng of the reporter p21LUC. The b-galactosidase
expressing pCMV-bgal vector (50 ng) (Stratagene) was
included to determine transfection efﬁciency. Cells were
harvested 24 h post transfection and luciferase activities
measured using the dual light luciferase and b-galactosi-
dase kit (TROPIX) on a Luminoskan RT dual injection
luminometer (Labsystems). All reporter gene assays were
carried out in independent triplicate experiments and
repeated at least three times. The luciferase values varied
1–12% among the parallels.
Results
The aPKCs i/k and f interact with the zinc ﬁnger DBD
of the Kru ¨ppel-like transcription factor family
In an attempt to ﬁnd novel interaction partners for the
aPKCs, we performed a yeast two-hybrid screen using a
HeLa cell cDNA expression library together with the reg-
ulatory domain of PKCk as bait. Three out of 68 positive
clones were identiﬁed as the C-terminal zinc ﬁnger region
of the Kru ¨ppel-like transcription factor TIEG1 (Fig. 1a).
The interaction was conﬁrmed in vitro by GST pulldown
assays using GST fusions of the zinc ﬁnger DBD of TIEG1
(TIEG1(DBD)) and the N-terminal proline-rich region of
TIEG1 (TIEG1(1–362)), and in vitro translated PKCk.A s
can be seen from Fig. 1d, no interaction was detected with
the N-terminal part of TIEG1. To further evaluate the
interaction between full-length TIEG1 and full-length
PKCi GST pulldown assays with GST-TIEG1 and whole-
cell extract isolated from HeLa cells were performed.
Western blot analysis of the pulled-down proteins with an
antibody recognizing both PKCi and PKCf showed that
both kinases interact with full-length TIEG1 (Fig. 1b).
Finally, co-immunoprecipitation assay using U2OS cells
overexpressing EGFP-TIEG1 veriﬁed that TIEG1 and
PKCi interacted in HeLa cells (Fig. 1c).
TIEG1 is a member of the KLF family of three zinc
ﬁnger proteins. The three zinc ﬁngers constitute the DBD,
which is highly conserved within the KLF family. In
addition to DNA binding, the zinc ﬁnger motifs may also
function in protein-protein interactions that modulate
DNA-binding speciﬁcity [13]. Thus, to determine whether
PKCk had the ability to interact with other members of the
KLF family, we conducted GST pulldown assays with
PKCk and the KLF family proteins Sp1, Sp3, BTEB1 and
BTEB2. Interestingly, PKCk was found to interact with the
DBD of all KLF family proteins tested (Fig. 1d), sug-
gesting that aPKCs may be general interaction partners of
KLF family proteins.
The KLF family of transcription factors are substrates
for atypical PKCi and f in vitro
The Kru ¨ppel-like transcription factor Sp1 has been repor-
ted to be a target for PKCf-mediated phosphorylation in
several reports (reviewed in [14]). The interaction between
TIEG1 and the aPKCs i and f raised the question whether
TIEG1 is also a substrate for these kinases. Full-length
TIEG1 expressed as a MBP fusion in E. coli was incubated
with recombinant PKCi or PKCf in an in vitro kinase
assay. Both kinases had the ability to phosphorylate TIEG1
(Fig. 2a), and the phosphorylation increased linearly within
a time period of 90 min (Fig. 2b). We also included the
KLF proteins KLF4 and the closely related KLF11 (also
called TIEG2) in a phosphorylation assay. Both proteins
were PKCi/f substrates (Fig. 2c and data not shown),
supporting the notion that the aPKCs are putative regula-
tors of KLF family proteins. To determine whether the zinc
ﬁnger DBD or the N-terminal proline-rich regions were
substrates for the aPKCs, each of these regions was
1958 E. A. Alemu et al.
123expressed as GST fusions and incubated with recombinant
PKCf in an in vitro kinase assay. The N-terminal proline-
rich region of TIEG1 was clearly not a PKCf substrate,
whereas the zinc ﬁnger DBD was heavily phosphorylated
(Fig. 2e).
The fact that the conserved DBD of TIEG1 is a PKCsi/f
substrate encouraged us to investigate whether this would
be the case for the DBD of the KLF transcription factors
found to interact with PKCi and f in this study. All four
KLFs were PKCi/f substrates in vitro (Fig. 2f). Sp1(DBD),
which is a known PKCf substrate, and BTEB1(DBD) were
more heavily phosphorylated than Sp3(DBD) and
BTEB2(DBD). Taken together, the results suggest that the
aPKCs may regulate KLF family proteins by phosphory-
lating their DBDs.
S384 and T445 of TIEG1 are phosphorylated by PKCf
As mentioned above, the zinc ﬁnger DBD of the KLF
factors are highly conserved (Fig. 3a). Four residues within
the DBD of Sp1 are reported to be phosphorylated by
PKCf: S641 in zinc ﬁnger 1, and T668, S670 and T681 in
zinc ﬁnger 2 (reviewed in [14]). Phosphorylation of S641
leads to release of the inhibitor p107 from Sp1 bound to the
luteinizing hormone receptor (LHR) promoter, thereby
activating transcription of the LHR [19]. T668, S670 and
T681 in zinc ﬁnger 2 are phosphorylated by PKCf upon
angiotensin II stimulation, leading to activation of the
PDGF-D promoter [20]. In order to map the speciﬁc resi-
dues in TIEG1 phosphorylated by PKCf, we chose to focus
on S384, which is positioned in the recognition helix of
Fig. 1 PKCs f and i interact with the KLF family zinc ﬁnger domain
in vitro and in HeLa cells. a Schematic representation of the domain
structure of TIEG1. The three zinc ﬁnger motifs constituting the
DNA-binding domain are represented by ﬁlled boxes. The TIEG1
region isolated in the yeast two-hybrid screen is indicated by the solid
line below the schematic. b Whole-cell extracts from HeLa cells were
incubated with equal amounts of bacterially expressed GST or GST-
TIEG1 immobilized on glutathione-sepharose beads. The presence of
aPKCs in the pulled-down proteins were examined by immunoblot-
ting using aPKCf(C20) antibody that recognizes both PKCf and
PKCi. c U2OS cells were transfected with either GFP or GFP-TIEG1.
The cells were lysed 24 h post transfection, and immunoprecipitations
were performed using anti-GFP antibody. Western blots of the
immunoprecipitates and of the cell extract were revealed using
monoclonal anti-PKCk antibody (left panel) and immunoprecipitated
GFP or GFP-TIEG1 proteins were visualized using polyclonal anti-
GFP antibody (right panel). d Myc-tagged PKCk was in vitro
translated in the presence of [
35S] methionine and incubated with
equal amounts of either glutathione-sepharose beads coupled GST or
GST-tagged KLF family proteins. The pulled-down proteins together
with 5% of the input were subjected to detection by autoradiography
(upper panel). The levels of GST or GST-tagged proteins used in the
GST pulldown assays were examined by Coomassie brilliant blue
staining (lower panel). The data shown in b, c, and d correspond to a
representative experiment out of two performed
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123zinc ﬁnger 1 similarly to S641 of Sp1 (Fig. 3a), and T445
located in the recognition helix of zinc ﬁnger 3. None of
these residues are involved in direct contact with DNA
bases, but they are positioned next to amino acids that are
important for sequence-speciﬁc DNA binding (Fig. 3a).
Substitution of S384 and T445 with alanine signiﬁcantly
reduced the PKCf-mediated phosphorylation of the TIEG1
DBD in an in vitro phosphorylation assay (Fig. 3b). This
was conﬁrmed by introducing the same alanine substitu-
tions into the full-length TIEG1 protein (supplementary
material Fig. S1), where the single alanine mutants led to
reduction in the phosphorylation of TIEG1. However,
introducing the double mutations did not lead to a complete
loss of PKCf mediated phosphorylation (supplementary
material Fig. S1). This suggests that other serine and/or
threonine residues within the TIEG1 DBD may act as
substrates for this kinase. T445 is located in the same
position as S702 in Sp1. This residue is not a known PKCf
substrate. In order to investigate whether Sp1 S702 was a
PKCf target, an Sp1 S702A mutant was subject to an in
vitro phosphorylation assay. Interestingly, PKCf-mediated
phosphorylation of the Sp1 S702A mutant was reduced to a
similar degree as that of the well-known Sp1 S641A
mutant (Fig. 3c), indicating Sp1 S702 as a novel target for
Fig. 2 The KLF family
proteins are phosphorylated by
the atypical PKCs f and i.
a, c Both PKCf and PKCi
phosphorylate TIEG1 (a) and
KLF4 (c) in vitro. The
phosphorylation assays were
performed for 20 min at 30Ci n
30-ll reaction volume
containing MBP, and MBP-
TIEG1 or MBP-KLF4 as
substrate, 50 ng recombinant
active PKCf (upper panels)o r
PKCi (lower panels)6 0lM
unlabeled ATP and 2 lCi
[
32P]-ATP. The reactions were
analyzed by autoradiography.
b, d The phosphorylation of
TIEG1 (b) and KLF4 (d)b y
PKCf is linear with time. The
upper panels are bar graphs
showing the quantiﬁcation of
the phosphorylation levels of
TIEG1 and KLF4 over the
indicated time points,
respectively, and the lower
panels are the corresponding
autoradiographs. e, f The
DNA-binding domains of KLF
family proteins are targets
for PKCf-mediated
phosphorylation. GST,
GST-TIEG1(1–362) and
GST-TIEG1(DBD) (e),
and GST, GST-tagged DBDs
ofKLF family proteins (f) were
subjected to in vitro
phosphorylation and subsequent
analysis by autoradiography.
The data in a, c, e and f are
representative of three
independent experiments. The
data in b and f are shown as
the mean (± SD) of four
independent experiments
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123PKCf. The mapping of the Sp1 S702 and TIEG1 T445
residues as targets for PKCf also explains why the Sp3-
and BTEB2 DBDs were less phosphorylated than the Sp1-
and TIEG1 DBDs (Fig. 2f). The Sp3- and BTEB2 DBDs
have an A at the site corresponding to Sp1 S702 and TIEG1
T445 (Fig. 3a). Taken together, these results show that
conserved serine and threonine residues within the recog-
nition helices of zinc ﬁngers 1 and 3 of TIEG1 and Sp1 are
potential targets for PKCf mediated phosphorylation.
Phosphorylation of S384 inhibits the DNA-binding
activity of TIEG1
PKCf-mediated phosphorylation of Sp1 has been reported
both to increase and decrease DNA binding (reviewed in
[14]). In order to investigate whether PKCf-mediated
phosphorylation of TIEG1 would compromise or stimulate
DNA binding, we performed GMSA with the S384A and
T445A mutants and the double mutant S384A/T445A.
Fig. 3 PKCf phosphorylates TIEG1 at Ser 384 located in zinc ﬁnger
1 and Thr 445 located in zinc ﬁnger 3. a Amino acid sequence
alignment of the DBDs of the KLF family proteins. Conserved
residues are shaded, and the core zinc ﬁnger domains are indicated by
thick lines and labeled ZF 1–3. The locations of the phospho-
acceptors Ser 384 and Thr 445 residues are boxed. Below and to the
left is the structure of the zinc ﬁnger protein ZNF268 [57] with the
location of the phosphorylation sites in the recognition helixes of zinc
ﬁngers 1 and 3 indicated by arrows. Below and to the right are the
amino acid sequences of zinc ﬁngers 1 and 3 in TIEG1. The amino
acids within the recognition helix that are proposed to contact the
DNA bases are indicated by solid lines. The prediction is based on
the NMR structure of Sp1 [58]. Ser 384 and Thr 445 are shown in
bold. b, c Mutations of TIEG1S384 and TIEG1T445 (b), and
Sp1S641 and Sp1S702 (c) to alanine signiﬁcantly reduce their
PKCf-mediated phosphorylation. Equal amounts of GST and GST-
tagged TIEG1 proteins (b), GST and GST-tagged Sp1 proteins
(c) were subjected to in vitro phosphorylation assays; detection and
quantiﬁcation as described above. Shown are the quantiﬁed phos-
phorylation levels as bar graphs (upper panels), autoradiographs
(middle panels) and Coomassie staining indicating the levels of GST
and GST-tagged proteins used in the in vitro kinase assays (lower
panels). Each bar in b and c represents the mean (± SD) of four
independent experiments
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stronger afﬁnity for DNA than the wild-type protein
(Fig. 4a). To mimic phosphorylation of these residues, the
S384E, T445E and S384E/T445E mutants were generated
and used in GMSA. No DNA binding could be detected for
the S384E and S384E/T445E mutants. The T445E mutant,
however, bound DNA with similar afﬁnity as the wild type.
These results suggest that phosphorylation of S384 impairs
DNA binding, while phosphorylation of T445 has no effect
on DNA binding.
In order to determine whether TIEG1 DBD phosphor-
ylated by PKCf would have similar DNA-binding
properties as the S384E/T445E mimicking mutant, the
TIEG1 DBD wild-type and double alanine mutant versions
were phosphorylated by PKCf before performing gel shift
assays. Pre-phosphorylated TIEG1 DBD binds DNA with
signiﬁcantly less afﬁnity than the unphosphorylated forms
(Fig. 4b). Notably, the phosphorylated TIEG1 DBD
S384A/T445A mutant showed less afﬁnity for DNA than
the unphosphorylated forms, indicating the presence of
additional PKCf phosphorylation sites within the TIEG1
DBD. Furthermore, the effects of PKCf-mediated phos-
phorylation on DNA binding were investigated for the
KLF family proteins Sp1 and KLF4. Surprisingly, phos-
phorylation of the KLF4 and Sp1 DBDs did not seem to
affect DNA binding at all (Fig. 4c). Hence, PKCf phos-
phorylation of the DBDs of KLF family proteins may
increase, decrease or have no effect on DNA-binding
activity depending on the speciﬁc KLF protein and the
speciﬁc phosphorylation site involved. For instance, as
shown here, phosphorylation of TIEG1 S384 in the
recognition helix of zinc ﬁnger 1 clearly impaired its
DNA-binding activity.
The phospho-mimicking mutants of TIEG1 display
a redistributed subnuclear localisation
To explore whether phosphorylation of S384 and/or T445
had an impact on the nuclear localization of TIEG1, GFP
fusions of wild-type TIEG1 and the six mutants S384A,
S384E, T445A, T445E, S384A/T445A and S384E/T445E
Fig. 4 PKCf-mediated phosphorylation of TIEG1S384 impairs its
DNA-binding activity. a–c Gel mobility shift assays (GMSA)
demonstrating the effects of phospho-mimicking substitutions or in
vitro phosphorylation on the DNA-binding ability of KLF proteins.
a Substitution of Ser 384 to glutamate abolishes the DNA-binding
ability of TIEG1. GMSA using GST and GST-fused TIEG1 proteins,
and [
32P]-ATP labeled oligonucleotides containing consensus TIEG1-
binding sites described in [17]. The binding reactions were separated
on non-denaturating polyacrylamide gels that were vacuum dried and
analyzed by autoradiography (upper panel). The lower panel shows
control protein staining indicating the amounts of proteins used in the
assays. b Pre-phosphorylation of TIEG1(DBD) by PKCf also impairs
DNA binding. Here, GST and GST-fused TIEG1 proteins were pre-
incubated with PKCf in the presence or absence of ATP prior to
GMSA. c PKCf-mediated phosphorylation of the DBDs of KLF4 and
Sp1 does not impair their DNA-binding activity. GMSA with GST
and GST-KLF4(DBD) (left panel), and GST and GST-tagged
Sp1proteins (right panel). The proteins were pre-treated with PKCf
and/or ATP prior to GMSA using [
32P]-ATP labeled oligonucleotide
containing consensus KLF-binding sites described in [18]. The data
shown are representative of three independent experiments
c
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123were expressed in HeLa and U2OS cells. The subcellular
distribution of the GFP-fusion proteins was investigated by
confocal ﬂuorescence microscopy. In both cell lines, wild-
type TIEG1 is localized in the nucleus but excluded from
the nucleoli, with a weak staining in the nucleoplasm and
enrichment in several speciﬁc irregular speckles or bodies
(Fig. 5a, upper panels). Interestingly, GFP-TIEG1 S384E
or GFP-TIEG1 T445E was redistributed into speciﬁc round
nuclear bodies (Fig. 5a, middle panels). This redistribution
into round nuclear bodies is most prominent for the double
mutant GFP-TIEG1 S384E/T445E (Fig. 5a, lower panels),
and the phenotype is displayed by about 50% of the
transfected cell population. To address the question whe-
ther the observed subnuclear redistributions are a simple
consequence of overexpression or not, we performed
ﬂuorescence recovery after photobleaching (FRAP) anal-
ysis with the wild-type and the double mutant forms of
GFP-TIEG1. As shown in Fig. 5b, the round nuclear dots
of GFP-TIEG1 S384E/T445E are not simple aggregates
since their mobility is similar to that of the wild type and
the S384A/T445A mutant. Taken together, these results
suggest that phosphorylation of TIEG1 DBD may recruit
the protein to speciﬁc dynamic nuclear structures.
Phosphorylation of T445 enhances the transactivation
potential of TIEG1
Overexpression of TIEG1 is shown to mimic TGFb activity
in several cell lines [21–23] and to enhance TGF-b1
expression [24]. TIEG1 has also been found to increase
TGFb-induced expression of the cyclin-dependent kinase
inhibitor p21
Cip1/WAF1 [22]. Here, we conducted reporter
gene assays using the p21
Cip1/WAF1 promoter cloned in front
of the luciferase gene to determine whether the phosphor-
ylation of TIEG1 DBD at S384 and/or T445 would impact
its transactivation potential. As shown in Fig. 6a, overex-
pressionofwild-typeTIEG1increasedluciferaseexpression
from the p21
Cip1/WAF1 promoter six- to nine-fold. The
transactivation was strongly increased up to 25-fold when
TIEG1 containing the T445E mutation was coexpressed,
suggesting that phosphorylation of T445 positively regu-
lates its transcriptional activation potential. Consistent with
Fig. 5 Mutation of TIEG1 Ser 384 and Thr 445 to glutamate induces
subnuclear relocalization. a The phospho-mimicking mutants of
TIEG1 are enriched in round nuclear bodies. HeLa and/or U2OS cells
were transfected with an expression construct for EGFP-TIEG1 or
EGFP-tagged TIEG1 mutants and imaged by confocal laser ﬂuores-
cence microscopy 24 h post transfection. b The TIEG1 mutants
display mobility similar to the wild-type TIEG1. HeLa cells were
transfected with the indicated constructs, and 24 h post transfection
the cells were imaged and ﬂuorescence signals were collected before
and after photobleaching a portion of the nucleus. The recovery
kinetics were calculated after double normalization of the initial
ﬂuorescence, corrected for background and loss of ﬂuorescence
caused by imaging. The graph presented here shows the average
intensity of the bleach spot of 9–10 independent cells for the indicated
time points. Error bars represent the SD values between various
experiments
c
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when the T445A mutant was co-expressed. Surprisingly, the
S384E and the S384E/T445E mutants, which we found had
lost their DNA-binding activity, still had the capacity to
stimulate expression from the p21
Cip1/WAF1 promoter
(Fig. 6a).Alikelyexplanationforthisobservationisthatthe
mutants with compromised DNA-binding activity are
recruited to the promoter by endogenous TIEG1 and/or
other KLF family proteins. The p21
Cip1/WAF1 promoter
contains six adjacent GC boxes close to the transcriptional
start site that have the potential to recruit KLF family pro-
teins (Fig. 6a). We found that TIEG1 (and other KLF
proteins too) has a strong capability to form homo- and
heterodimers with KLF family proteins via interactions
involving the DBDs (Fig. 7, and supplementary material
Fig. S2). This interaction is not dependent on the presence
of nucleic acids as evidenced by benzonase treatment
(Fig. 7c, d). The homo- and heterodimerization potential of
the TIEG1DBD is not impaired by phosphorylation of S384
or T445 (supplementary material Fig. S3). Thus, TIEG1
mutants with impaired DNA-binding activity may be
recruited to speciﬁc promoter sites by interaction with
endogenous KLF factors bound to the promoter.
Sp1 is a well-known activator of the p21
Cip/WAF1 pro-
moter. Phosphorylation of Sp1 on T453, T739 [25] or S59
[26] has been shown to induce expression of p21
Cip1/WAF1
and cellular senescence. Additionally, PKC [27], PKG [28]
and high-glucose induced p21
Cip1/WAF1 expression is medi-
ated by Sp1 binding to the p21
Cip1/WAF1 promoter. To
examine whether other KLF family proteins were potential
activators of the p21
Cip1/WAF1 promoter, luciferase reporter
assays were performed with KLF4, KLF11 and EGR1 in
additiontoSp1andTIEG1(Fig. 6c).BothKLF11andEGR1
induced expression from the p21
Cip1/WAF1promoter, KLF11
(TIEG2) with a similar potency as TIEG1. KLF4, on the
other hand, did not cause signiﬁcant activation of the pro-
moter. When we replaced the DBD of TIEG1 with the DBD
of Sp1, the hybrid transcription factor also induced the
p21
Cip1/WAF1 promoter although less potently than Sp1 and
TIEG1. Furthermore, we found overexpression of EGR1 to
besigniﬁcantlylesstoxicthanoverexpressionofTIEG1,Sp1
and KLF11 (data not shown), although EGR1 also induced
p21
Cip1/WAF1 expression. This suggests that apoptosis
induced by Sp1-like family proteins may involve additional
mechanisms besides p21
Cip1/WAF1 upregulation. This cor-
relates well with reports showing that TIEG1 induces
apoptosis through the mitochondrial apoptotic pathway
upregulating Bax and Bim, and downregulating Bcl-2 and
Bcl-XL [29], and KLF11 inducing oligodendroglial cell
death by downregulation of Bcl-X expression [30].
Fig. 6 The TIEG1T445E mutant displays enhanced transactivation
potential. a U2OS cells were transiently transfected with 0.1 lg of the
reporter p21-LUC, together with the expression vectors for TIEG1
and TIEG1 mutants as indicated and subjected to reporter gene assay
analysis. The data represent the mean of two independent experiments
performed in triplicates. Error bars represent the SD values between
various experiments. b Total cell extracts from the transfected U2OS
cells were prepared, and the levels of TIEG1 proteins were analyzed
by Western blotting using anti-GFP antibody (upper panel) and then
with anti-actin antibody as loading control (lower panel). c All KLF
family proteins tested except KLF4 are potential activators of the
p21
Cip1/WAF1 promoter. The reporter gene assay data shown is from
one experiment performed in triplicate, which is representative of
three independent experiments each performed in triplicate. Error
bars represent the SD values between the parallels. d Western blot
analysis of extracts from transfected U2OS cells to show the
expression level of the various KLF family proteins
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In this study we have shown that TIEG1 is an interaction
partner and substrate for aPKCs. Two residues in the DBD,
S384 and T445 in zinc ﬁngers 1 and 3, respectively, were
found to be the major sites phosphorylated by recombinant
aPKCs. Substitution of S384 by the phospho-mimicking
glutamate (S384E) resulted in inhibition of DNA binding,
while the T445E mutant displayed an enhanced transacti-
vation potential relative to the wild-type protein. Both
mutations led to a subnuclear redistribution of the protein
into round, dynamic nuclear bodies. In addition, we show
that the DBDs of various KLF family proteins are targets
for PKCf/i-mediated phosphorylation and that the KLF
proteins have a strong ability to form homo- and hetero-
dimers via their DBDs.
Sp1 is phosphorylated by PKCf [20, 31–36] (reviewed
in [14]). PKCf-mediated phosphorylation of S641 in zinc
ﬁnger 1 of Sp1 does not affect its DNA-binding activity,
but leads to release of the p107 inhibitor and thereby
enhanced transcriptional activation [36]. In contrast, here
we report that PKCf-mediated phosphorylation of TIEG1
at S384, which corresponds to S641 of Sp1, strongly
inhibited DNA binding. However, the transcriptional
activity of the TIEG1 S384E mutant on the p21
Cip1/WAF1
promoter was less affected. This suggests that even if KLF
family proteins are phosphorylated at corresponding amino
acid residues, the biological outcome of the phosphoryla-
tion may be speciﬁc to the particular KLF factor involved.
We have also shown that corresponding residues in zinc
ﬁnger 3 of TIEG1 and Sp1 are targets for PKCf-mediated
phosphorylation. The phospho-mimicking mutant TIEG1
T445E signiﬁcantly enhanced TIEG1-induced activation of
the p21
Cip1/WAF1 promoter. Interestingly, Sp1 S702 is also
reported to be modiﬁed by the monosaccharide O-linked
b-N-acetylglucose amine (O-GlcNAc) [37]. O-GlcNAcy-
lation of Sp1 has been shown to increase [37–43]o r
decrease [42, 44] its transcriptional activity depending on
the target promoter. O-GlcNAc and phosphate modiﬁca-
tions on substrates are shown to interact in various ways
both at the global cellular protein level and at speciﬁc sites
on particular proteins (reviewed in [45]). For instance, they
can competitively and alternatively occupy the same serine
or threonine residue, or they can regulate each other by
generating large functional complexes. Hence, phosphory-
lation of Sp1 S702 may regulate and/or communicate with
Fig. 7 KLF family proteins have the ability to homo- and
heterodimerize via their DNA-binding domain. a–c GST pulldown
assays were carried out using bacterially expressed GST, or the
indicated GST-tagged proteins, and in vitro translated either full-
length HA-TIEG1 (a, b) or GFP-TIEG1(DBD) (c). Autoradiographs
are presented in the upper panels, whereas Coomassie brilliant blue
stained SDS-polyacrylamide gels are shown in the lower panels.
c, d TIEG1 homodimerization is not mediated by nucleic acids in the
reaction mixture. GFP-TIEG1(DBD) was in vitro translated and
divided into two. One half was used directly for GST pulldown assays
(c, right panel), and the remaining half was treated with 250 units of
benzonase for 20 min at room temperature prior to GST pulldown
assays (c, left panel). d The benzonase used in the assay was active.
The expression construct, GFP-TIEG1(DBD), was either treated with
benzonase or left untreated, and the reaction analyzed on a 0.7%
agarose gel followed by ethdium bromide staining. Data shown are
representative of two independent experiments
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ulate its transcriptional activity. Furthermore, Sp1 S702 is
located next to Sp1 K703, which is reported to be targeted
for acetylation [46]. Acetylation of Sp1 K703 recruits
HDAC1 to the Sp1 located promoter sites and represses
transcription, while deacetylated K703 recruits p300 and
induces transcription. Hence, phosphorylation and/or gly-
cosylation of S702 and acetylation of K703 may interact
with each other in an agonistic or antagonistic manner, and
thereby integrate diverse signaling cues at the transcrip-
tional level through Sp1 bound at promoter sites.
Interestingly, we also found TIEG1 to be modiﬁed by
O-GlcNAc (E. Alemu and T. Johansen, unpublished data).
O-GlcNAc modiﬁcations of proteins are believed to con-
stitute an important regulatory pathway that controls protein
activity according to glucose availability. O-GlcNAc
modiﬁcation of Sp1 has been connected to glucose sensing,
expression of glucose transporters and in various aspects of
hyperglycaemic-induced glucotoxicity (reviewed in [47]),
whereas TIEG1 is involved in the regulation of circadian
gene expression, which is trigged by glucose [48]. Inter-
estingly, aPKCs are heavily involved in regulation of
glucose transport and insulin sensitivity [7]. Our in vitro
data suggest that aPKCs at least partly may exert this reg-
ulation via post-translational modiﬁcations of Sp1 and
TIEG1. Additionally, TIEG1 contains a lysine residue
(K446), which lies next to the PKCf targeted site (TIEG1
T445). Whether this lysine as well is a target for post-
translational modiﬁcations, such as acetylation, has not
been reported yet.
Overexpression of TIEG1 induces apoptosis by acti-
vating TGFb-regulated signaling pathways [23, 49, 50]
(reviewed in [12]) and promoting mitochondrial apoptotic
pathways [29]. TIEG1 overexpression is reported to
increase the expression of the cyclin-dependent kinase
inhibitor p21
Cip1/WAF1 and signiﬁcantly decrease cellular
proliferation. Here we show that TIEG1 is a potent acti-
vator of the p21
Cip1/WAF1 promoter and that a phospho-
mimicking mutation of TIEG1 T445 signiﬁcantly enhances
this activation. In general, Sp1 family transcription factors
are reported as major regulators of p21
Cip1/WAF1 tran-
scription (reviewed in [51, 52]). The p21
Cip1/WAF1
promoter contains six binding sites for Sp1 family proteins
at the proximal promoter (bp -120 to -50), and mutations
of these sites signiﬁcantly affect synergistic activation by
Sp1, p53 and other signals that regulate transcription of the
p21
Cip1/WAF1 gene [52, 53]. Importantly, the transcriptional
activity of Sp1 has been reported to be regulated by
phosphorylation by various kinases at different sites, and
these signaling events are integrated at GC-box containing
promoters (reviewed in [14]). We found that the aPKCs
phosphorylate Sp1 and TIEG1 at corresponding sites in the
DBD. Both proteins are reported to induce p21
Cip1/WAF1
expression upon various stimuli, via the six promoter
proximal GC boxes. GC box 3 is shown to mediate
p21
Cip1/WAF1 induction by agents such as TGFb and his-
tone deacetylase inhibitors, whereas GC boxes 1 and 2 are
important for transcriptional activation mediated by phor-
bol esters and okadaic acid (reviewed in [52]). The aPKCs
are involved in cell polarity processes, metabolic regula-
tion and cell survival signaling, and PKCi is also reported
to act as an oncogene when its gene is ampliﬁed in lung
and ovarian cancers (reviewed in [4]). Hence, one would
expect that aPKCs could have a negative effect on the
suggested tumor suppressor TIEG1. This effect could be
exerted via S384 phosphorylation. However, aPKC could
also act positively via phosphorylation of T445. We found
that the S384E/T445E double mutant strongly reduced the
p21
Cip1/WAF1 induction seen with the T445E mutant alone.
The effect of aPKC phosphorylation of the TIEG1 DBD
may therefore depend on the accessibility of these sites.
The above-mentioned O-GlcNAcylation and acetylation
may be involved in regulating this accessibility.
How post-translational modiﬁcations of Sp1 inﬂuence
its afﬁnity for DNA and other proteins is only beginning to
become apparent. Sp1 can interact with components of the
basal transcription machinery, as well as transcription
factors, coactivators and corepressors. Several of these
interactions are regulated by post-translational modiﬁca-
tions of Sp1. This protein also has a strong tendency to
interact with itself [54] and with other members of the KLF
protein family (this work). In addition, there is direct
binding competition among KLF family proteins on
GC-rich promoter sequences ([55] and ref. therein). Our
present results show that various activities of TIEG1
including DNA binding, transcriptional activation and
subnuclear localization are also regulated by post-transla-
tional modiﬁcations, suggesting that this is most probably a
general feature of KLF family proteins. Moreover, our data
indicate that KLF family proteins may offer a large number
of combinatorial possibilities to regulate expression from
GC box containing promoters, making them important
candidates for integrating various cellular signaling events
at the transcriptional level.
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